Impact BioMedical Inc. (IBO) stock
IBONYSEPharmaceutical PreparationsFiscal year ends December 31
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026Market cap $26.14MP/E –Yield –
Impact BioMedical ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Impact BioMedical's ebitda for the twelve months ending Sep 30, 2026 was -$3.67M. For fiscal 2025 it was -$3.14M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$3.14M | – |
| FY2024 | Dec 31, 2024 | -$27.63M | – |
| FY2023 | Dec 31, 2023 | -$2.91M | – |
| FY2022 | Dec 31, 2022 | -$2.29M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$364.00K | – |
| Q2 FY2026 | Jun 30, 2026 | -$418.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.00M | – |
| Q4 FY2025 | Dec 31, 2025 | -$884.00K | – |
| Q3 FY2025 | Sep 30, 2025 | -$660.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$865.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$727.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$25.95M | – |
| Q3 FY2024 | Sep 30, 2024 | -$846.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$347.00K | – |
| Q1 FY2024 | Mar 31, 2024 | -$491.00K | – |
| Q4 FY2023 | Dec 31, 2023 | -$859.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$798.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$728.00K | – |
| Q1 FY2023 | Mar 31, 2023 | -$523.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$754.00K | – |
| Q3 FY2022 | Sep 30, 2022 | -$610.00K | – |
| Q2 FY2022 | Jun 30, 2022 | -$472.00K | – |
See a number that looks wrong?